【摘要】 目的观察瑞舒伐他汀治疗急性冠脉综合征患者白细胞介素-6(IL-6)、血浆α-颗粒膜蛋白(GMP-140)、脑钠素(BNP)和心功能的变化。方法 80例急性冠脉综合征患者随机分为两组,对照组40例给予常规治疗;治疗组40例在对照组治疗的基础上加用瑞舒伐他汀口服。两组疗程均为32周。结果治疗32周治疗组血清IL-6、GMP-140和BNP显著低于对照组(P<0.01),左室射血分数(LVEF)明显改善(P<0.01),对照组无明显变化。结论瑞舒伐他汀治疗急性冠脉综合症患者可以使血清IL-6、GMP-140和BNP水平显著下降,减轻炎症反应,抑制血小板活化,稳定动脉粥样硬化斑块,改善心功能。更多还原

【Abstract】 Objective To observe the clinical effect of rosuvastatin plasma IL-6,GMP-140,BNP levels and heart function in patients with acute coronary syndromes. Methods 80 cases of acute coronary syndromes patients were randomly divided into two groups. 40 cases in control group were given conventional treatment while 40 cases in treatment group were given oral rosuvastatin based on the control group treatment. Both groups were treated for 32 weeks. Results After the treatment,in treatment group,serum IL-6、GMP-140 and BNP were significantly lower than those in the control group( P < 0. 01). LVEF was increased in treatment group,while these were not significant change in treatment group. Conclusions Rosuvastatin treatment of acute coronary syndromes can have a significant reduction in serum IL-6,GMP-140 and BNP level,reduce inflammation reaction,inhibit activation of platelet,stable atherosclerotic plaque,and improve heart function.更多还原